相关实验视频

Updated: Sep 8, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

3βHSD1抑制剂的精细结构设计用于前列腺癌治疗

Dongyin He¹, Luyao Zhang^2,3, Leiye Yu^4,5

¹Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.

Proceedings of the National Academy of Sciences of the United States of America

|June 25, 2025

概括

研究人员开发了HEAL-116,这是一种针对3β-基类固醇脱酶1型 (3βHSD1) 的新型抑制剂,用于对抗前列腺癌. 这种化合物显示出改善的口服生物利用性和强大的抗瘤作用,提供了一个新的治疗途径.

科学领域:

生物化学和分子生物学
计算化学计算化学
在瘤学瘤学.

背景情况:

前列腺癌是一个全球性的健康挑战,特别是在目前治疗方法耐药的情况下.
酶3β-hydroxysteroid脱酶1型 (3βHSD1) 是前列腺癌的一个关键治疗点.
现有的抑制剂,如生物anin-A (BCA) 是有前途的,但其口服生物利用性较差.

研究的目的:

通过计算改进3βHSD1抑制剂的结构设计.
开发具有增强功效和改善药理动学的新型抑制剂.
建立为前列腺癌治疗3βHSD1抑制剂的临床转化奠定基础.

主要方法:

使用AlphaFold2来建模3βHSD1-基质相互作用.
采用计算方法和结构活动关系研究来优化BCA衍生品.
在生物化学,细胞和临床前小鼠模型中评估HEAL-116.

主要成果:

确定HEAL-116是一种强大的3βHSD1抑制剂,具有增强的结合特异性.
由于添加了水友性群体,HEAL-116的口服生物可用性得到了改善.
在各种模型中,HEAL-116表现出显著的抗瘤作用.

结论:

HEAL-116代表了一个有前途的下一代3βHSD1抑制剂,具有增强的特性.
开发的计算策略有效地引导了抑制剂优化.
这些发现支持3βHSD1抑制剂用于前列腺癌和其他疾病的临床转化.

关键词:

3βHSD1 的情况.阿尔法折叠是什么意思阿尔法折叠药物开发是药物的发展.分子模拟,分子模拟.前列腺癌是前列腺癌.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...